MX2013012486A - Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor). - Google Patents

Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).

Info

Publication number
MX2013012486A
MX2013012486A MX2013012486A MX2013012486A MX2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A MX 2013012486 A MX2013012486 A MX 2013012486A
Authority
MX
Mexico
Prior art keywords
pi3k
mtor
treating lymphoma
pyridopyrimidinone
inhibitors
Prior art date
Application number
MX2013012486A
Other languages
English (en)
Inventor
Arthur Decillis
Joanne Lager
Tal Zaks
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2013012486A publication Critical patent/MX2013012486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona un método para tratar los cánceres, incluyendo malignidades hematológicas que comprenden administrar de un compuesto de formula I:.
MX2013012486A 2011-04-29 2012-04-27 Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor). MX2013012486A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161480991P 2011-04-29 2011-04-29
US201161493998P 2011-06-07 2011-06-07
US201161566066P 2011-12-02 2011-12-02
PCT/US2012/035442 WO2012149308A1 (en) 2011-04-29 2012-04-27 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor

Publications (1)

Publication Number Publication Date
MX2013012486A true MX2013012486A (es) 2014-05-28

Family

ID=46062758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012486A MX2013012486A (es) 2011-04-29 2012-04-27 Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).

Country Status (14)

Country Link
US (1) US20140296265A1 (es)
EP (1) EP2701690A1 (es)
JP (1) JP2014513104A (es)
KR (1) KR20140040726A (es)
CN (1) CN103635183A (es)
AR (1) AR086209A1 (es)
AU (1) AU2012249500A1 (es)
CA (1) CA2834282A1 (es)
EA (1) EA201391606A1 (es)
MX (1) MX2013012486A (es)
TW (1) TW201311683A (es)
UY (1) UY34044A (es)
WO (1) WO2012149308A1 (es)
ZA (1) ZA201307952B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
BR112014010492A2 (pt) 2011-11-01 2017-04-25 Exelixis Inc n-(3-{[(3-{[2-cloro-5-(metóxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inibidor de fosfatidilinositol 3-cinase para o tratamento de malignidades linfoproliferativas
AU2015283671B2 (en) * 2014-07-04 2018-07-05 Lupin Limited Quinolizinone derivatives as Pl3K inhibitors
SI3497103T1 (sl) * 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2012504628A (ja) * 2008-09-30 2012-02-23 エグゼリクシス， インコーポレイテッド ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤
BRPI1006189A2 (pt) * 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
WO2011100319A1 (en) * 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2012065019A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha

Also Published As

Publication number Publication date
AR086209A1 (es) 2013-11-27
CN103635183A (zh) 2014-03-12
KR20140040726A (ko) 2014-04-03
EA201391606A1 (ru) 2016-01-29
US20140296265A1 (en) 2014-10-02
WO2012149308A1 (en) 2012-11-01
TW201311683A (zh) 2013-03-16
AU2012249500A1 (en) 2013-11-28
JP2014513104A (ja) 2014-05-29
CA2834282A1 (en) 2012-11-01
EP2701690A1 (en) 2014-03-05
ZA201307952B (en) 2014-06-25
UY34044A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
PH12017502141A1 (en) Compounds and their methods of use
MX2013011330A (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
PH12014502046B1 (en) Treatment of cancer with tor kinase inhibitors
GT201300238A (es) Imidazopiridazinas como inhibidores de quinasa akt
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2013012486A (es) Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).
MX2015007054A (es) Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
IN2014CN02671A (es)
MX350868B (es) Medicamentos y metodos para tratar cancer.